Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
124.38
-0.06 (-0.05%)
Nov 20, 2024, 4:00 PM EST - Market closed
Company Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs.
It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Ascendis Pharma A/S
| Country | Denmark |
| Founded | 2006 |
| IPO Date | Jan 28, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 879 |
| CEO | Jan Mikkelsen |
Contact Details
Address: Tuborg Boulevard 12 Hellerup, 2900 Denmark | |
| Phone | 45 70 22 22 44 |
| Website | ascendispharma.com |
Stock Details
| Ticker Symbol | ASND |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 0001612042 |
| CUSIP Number | 04351P101 |
| ISIN Number | US04351P1012 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jan Moller Mikkelsen | President, Chief Executive Officer, Member of Executive Board and Executive Director |
| Scott T. Smith | Chief Financial Officer, Executive Vice President and Member of Executive Board |
| Lotte Sonderbjerg | Executive Vice President, Chief Administrative Officer and Member of the Executive Board |
| Michael Wolff Jensen L.L.M. | Executive Vice President, Chief Legal Officer and Member of the Executive Board |
| Mads Bodenhoff | Senior Vice President of Finance and Principal Accounting Officer |
| Timothy J. Lee | Senior Director of Investor Relations |
| Flemming Steen Jensen | Executive Vice President of Product Supply and Quality |
| Dr. Kennett Sprogoe Ph.D. | Executive Vice President and Head of Research and Product Development |
| Dr. Stina Singel M.D., Ph.D. | Executive Vice President and Head of Clinical Development for Oncology |
| Joseph Kelly | Head of U.S. Commercial of Endocrinology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |